Fig. 1
From: Investigation of EZH2 pathways for novel epigenetic treatment strategies in oropharyngeal cancer
EZH2 expression in HPV+ and HPV- oropharyngeal cancer patients. a EZH2 RNA expression from tissue biopsies in HPV+ and HPV- oropharyngeal patient tissues measured by ddPCR absolute levels relative to EEF2 (EZH2:EEF2 ratio). Significant differences are seen between HPV+ and HPV- patients (p = 0.006). HPV positivity was determined by clinical p16 immunohistochemistry and confirmed by HPV-16 E6 and E7 ddPCR. b Pearson correlation of EZH2 expression in each patient tissue above with EGFR, TP53, MKI67, CCND1, MET and PTEN/PIK3C